ABSTRACT -Rather than acute inflammation, long-standing multiple sclerosis (MS) course is hallmarked by relentless axonal loss and brain atrophy, both with subtle clinical expression and scarcely visible on conventional MRI studies. Brain atrophy imaging has sophisticated methodological requirements, not always practical and accessible to most centers. Corpus callosum (CC) is a major inter-hemispheric white matter bundle, grossly affected by long term MS and easily assessed by MRI. To determine whether a practical imaging method can reliably follow presumed axonal loss in patients with progressive MS, we designed a 5-year prospective open label study, enrolling 128 consecutive patients (75 relapsing-remitting (RR) and 53 secondary-progressive (SP)), on regular immunomodulatory therapy compared to control group, formed by 23 patients with MRI considered normal. On a conventional best mid-saggital T1W, CC index (CCI) was obtained by measuring anterior, medium and posterior segments of CC, normalized to its greatest anteroposterior diameter using an orthogonal semi-automated linear system. CCI was measured at baseline and at least once yearly. Results were plotted intra-individually; baseline values were used as reference. At baseline, CCI was able to distinguish SP patients from RR and controls, and on follow-up, despite some overlap, demonstrated a progressive reduction from baseline on both RR and SP groups compared to controls. From the third year on, difference between SP and RR patients reached statistical significance, which did not correlated with disability measured by EDSS. So, a corpus callosum index proved practical and feasible to longitudinally demonstrate morphometric callosal changes with potential to be used as a tool for long-term follow-up, mostly in SP patients.
Multiple sclerosis: corpus callosum index Figueira et al. Multiple sclerosis (MS) is a systemic autoimmune disease with exclusive expression over the central nervous system (CNS), characterized, at least at presentation, in about 85% of cases, by a relapsing-remitting (RR) course. This RR course is the clinical expression of a temporal and spatial dissemination of a focal infl ammatory process, clinically represented by relapses, most of them followed by a more or less complete and spontaneous remission 1 . Despite this classical concept, current evidence points to a silent, more widespread and ongoing infl ammation, diffusely involving CNS, besides axonal loss, which has been demonstrated to occur early in the course of the disease and to be a key factor for progression of disability [2] [3] [4] [5] . So, as time goes by and infl ammation tends to slow down, relapses become rarer, giving place to a more relentless secondary progressive (SP) phase, hallmarked by axonal loss and brain atrophy. At this point, conventional measures used as endpoints in most pivotal short-term follow-up MS studies, such as number of relapses and magnetic resonance imaging (MRI) activity, characterized by T1 weighted (T1W) gadolinium enhancement (Gd+) and refl ecting infl ammation, lose sensitivity. Axonal loss in MS has scarce expression. Clinically, it leads to progressive and insidious changes in cognitive functions, such as memory and speed of mental processing, which impacts daily living activities but lacks specifi city and is rarely taken into account on therapeutic decisions. On conventional imaging, its paradigm is based on morphological changes, as intracellular iron deposition, expressed by T2W hypointense sign at subcortical gray matter nuclei 6 , and volume reduction, as formally expressed by changes in brain parenchymal fraction (BPF) 7 , both too complicated to be used on daily practice. Otherwise, as it occurs widely over the CNS, clinical-imaging correlates for axonal loss are poorly specifi c and require sophisticated methodology, being impractical to be used on bedside basis and inaccessible to most centers 8, 9 .
Corpus callosum (CC) is a major white matter bundle which plays an important role in functional interhemispheric integration, communicating cognitive information through homotopic, and some heterotopic, interconnections between the hemispheres 10, 11 . The CC is usually grossly affected by long-term disease 12 and, because of its functional relevance to inter-hemispheric information transfer, it might be one of the components of the complex pathological process that leads to cognitive changes in MS. Furthermore, it is one of the few white matter tracts that can be discretely identifi ed by conventional MRI, having sharply demarcated two-dimensional limits on a midsaggital T1W imaging. So, as a consequence of these anatomic and functional properties, it is reasonable to assume that CC morphometrics might be a possible marker for the integrity of these associative fi bers. Involvement of associative fibers leads to morphometric changes in CC, affecting inter-hemispheric transfer of information and it is a major pathological substrate for slowing of mental processing on long-term MS 9 .
METHOD
Sample -One-hundred and twenty eight consecutive non-selected patients, with diagnosis of clinically defi ned MS according to the International Panel criteria 13 and included in our institutional MS treatment program 12 , were followed for fi ve years, in an open-label trial. Sample demographics are shown in Table. All patients were on follow-up according to the standard protocol of our reference center, regularly using one of the available immunomodulatory drugs for at least two years and had no relapses on prior 12-month period. A control group was formed by twenty-three patients, submitted to a normal MRI study, for a non-infl ammatory neurological condition, such as epilepsy and headache.
Imaging -Patients were submitted to the same conventional brain MRI scanning protocol on baseline using a 1.5T Sigma Magneton scanner (Siemens AG, Germany), according to the Consortium of Multiple Sclerosis Centers Magnetic Resonance Imaging working group standard recommendations 14 , including an axial pre and post Gd T1W, saggital T1W and FLAIR, axial T2W and FLAIR. Serial imaging was repeated at least annually for a 5-year period, but Gd sequences were used only if clinically indicated. All MRI were analyzed by the same examiner (FF), and, at baseline study, data were compared to those of a blind radiologist, to achieve reproducibility.
Corpus callosum index (CCI) was obtained on a conventional best mid-saggital T1W image, using a simple orthogonal semi-automated system, by drawing a straight line at greatest anteroposterior diameter of CC and a perpendicular at its midline, owing to points a, b and c (Fig 1) . Anterior (aa´), posterior (bb´) and medium (cc´) segments of CC were . For comparison and validation purposes only, at the beginning of follow-up we obtained brain parenchymal fraction in all exams, using methodology previously described 7 .
Clinical evaluation -After a complete baseline study and fi nal diagnosis of MS, patients were introduced to our treatment center standard protocol, with an every threemonth routine clinical follow-up, including disability estimates by expanded disability status scale (EDSS) 16 , done at each consultation. A brief neuropsychological test battery, described elsewhere 9 , including memory, verbal fl uency, depression task and a paced auditory serial addiction The study was designed to enroll patients on regular clinical follow-up and treatment. Protocol of the study was analyzed and approved by Ethical Committee of our Hospital and all patients intended to be involved gave informed consent to it.
RESULTS
Baseline -On baseline, when compared to scores of a blind radiologist, CCI determination showed a interobserver disagreement of 0.92% (SD=.32; p= 0.003) 12 . At this point, CCI was compared to brain parenchymal fraction (BPF) that, despite being too complicated to be used in daily practice is a widely accepted standardized measure for total brain atrophy (Fig  2) . CCI showed a linear correlation with BPF on both groups of patients (R 2 =.301; p<.01), and was able to distinguish SP patients from RR and controls (p=.014 and p=.003, respectively) 12 . Then CCI was normalized to its mean value separately in RR and SP patient groups to study its correlation to PASAT, as a clinical scorer for speed of inter-hemispheric transfer of information, a function at least theoretically linked to callosal fi ber integrity. Results showed a linear correlation between PASAT score and normalized CCI measure both on RR (R 2 =.364; p<.01) and SP (R 2 =.431; p< .001) groups of patients (Fig 3) 12 .
Follow-up -The sample was then prospectively followed for a 5-year period, and measures where taken at least yearly. There was a slow progressive reduction in mean CCI, observed on both group of MS patients, markedly in SP group, but also among RR patients, when compared to control. These scores were completely independent from EDSS. After 3 years, the difference between RR and SP patients scores reached statistical signifi cance (p=.035), and after 5 years, there was a clear difference between the groups (p<.01), which was, still, independent of disability status rated by EDSS (Fig 4) .
DISCUSSION
As stated above, the progressive phase of MS is clinically marked by motor disability and cognitive dysfunction, resulting from axonal loss and brain atrophy. Most current tools for imaging and clinical follow-up rely on acute infl ammation paradigm, as well as most end-points of pivotal immunomodulatory drug studies. Nevertheless, brain atrophy measures might prove to be important markers of disease progression, as they refl ect the irreversible pathological process of cell damage 17 .
The aim of our present study is a search for a measure for follow-up of progressive MS patients, easy to be applied on a bedside basis, feasible to be reproduced by different observers, with some evidence of a clinical correlate to prove its anatomical and functional reliability. Our present series is composed by 128 patients on regular treatment with any of the available immunomodulatory drugs and has a 5-year prospective ambulatory follow-up. Conventional brain MRI was obtained annually, as part of a routine treatment program. A simple, semi-automated index, that could also be manually obtained, was calculated from a best mid-saggital T1W slice and showed a fair reproducibility on baseline, as matched to a scored examination of a blind expert radiologist. In spite of the low number of cases, CCI showed good anatomical and functional correlates. Anatomical correlate by matching to BPF, a well recognized and validated measure of whole brain atrophy, and functional by its linear relation to an also well validated cognitive functional measure, PASAT. At this point, CCI was sensitive enough to segregate RR from SP patients, despite the signifi cant overlap between these two populations.
There was considerable overlap between groups, on follow-up, but inter-group CCI scoring analysis showed two distinctive patterns: a slowly progressive reduction, mostly among RR patients group, and a pronounced reduction, more common on SP patients. Initially a trend, after a 3-year follow-up this difference became statistically signifi cant, allowing segregation between the groups.
More impressive information was obtained by intra-patient CCI scoring variation over time: a progressive reduction was observed on both groups, much more expressive among SP patients, from the early beginning of our study.
A particular group of 8 RR patients raises a very intriguing question as they showed what can be called a clinical-imaging mismatch: in spite of being clinically stable, with no relapses and no disability progression after a 5-year period, a relentlessly progressive callosal atrophy is evident, quite a similar behavior to SP patients. This small group might simply be on a transitional stage of the continuum between RR and SP phases. On the other hand, they may represent a "look beyond the clinics", anticipating at image what can be, later, expressed clinically as a progressive deterioration. In this last case, CCI could have a unique predictive value for evolution, impacting on prognosis and treatment strategies. We hope that the longterm follow-up of these patients would help answer these questions.
In conclusion, current paradigms for optimizing primary care in MS patients emphasizes not only reduction of infl ammation, leading to a reduction in relapses rate and MRI activity, but also a long-term efficacy, impacting on disability scores, cognitive changes and brain atrophy. Acute changes are widely accessed by conventional MRI while cell loss and brain atrophy, leading to more discrete and insidious changes, are frequently dismissed. Two-dimensional methods for assessing brain atrophy in MS, either by linear or area measures are easy to be obtained and proved very sensitive to longitudinal changes 8 . Otherwise, it seems reasonable to conclude that, in some way, any imaging protocol for long-term follow-up in MS should recommend the inclusion of at least one standardized brain atrophy scoring. In spite of the cross-sectional design of our study, the CCI was practical, with no sophisticated software requirements, and quite sensitive to callosal atrophy. So, it proved to have a potential to be used on long-term follow-up for patients with MS.
